WO2006039604A1 - Use of pregnancy specific glycoprotein for maturation of oocytes - Google Patents

Use of pregnancy specific glycoprotein for maturation of oocytes Download PDF

Info

Publication number
WO2006039604A1
WO2006039604A1 PCT/US2005/035386 US2005035386W WO2006039604A1 WO 2006039604 A1 WO2006039604 A1 WO 2006039604A1 US 2005035386 W US2005035386 W US 2005035386W WO 2006039604 A1 WO2006039604 A1 WO 2006039604A1
Authority
WO
WIPO (PCT)
Prior art keywords
oocyte
vitro
oocytes
female
maturation
Prior art date
Application number
PCT/US2005/035386
Other languages
French (fr)
Inventor
Daniel G. De Matos
Cam Anh Tran
Ann M. Clark
Stephen S. Palmer
Original Assignee
Applied Research Systems Ars Holding, N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems Ars Holding, N.V. filed Critical Applied Research Systems Ars Holding, N.V.
Priority to US11/575,398 priority Critical patent/US20070282162A1/en
Priority to EP05803981A priority patent/EP1794286A1/en
Priority to AU2005292374A priority patent/AU2005292374A1/en
Priority to JP2007534835A priority patent/JP2008514239A/en
Priority to CA002581048A priority patent/CA2581048A1/en
Publication of WO2006039604A1 publication Critical patent/WO2006039604A1/en
Priority to IL181907A priority patent/IL181907A0/en
Priority to NO20072159A priority patent/NO20072159L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0608—Germ cells
    • C12N5/0609—Oocytes, oogonia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/10—Conditioning of cells for in vitro fecondation or nuclear transfer

Definitions

  • the present invention is generally related to reproductive biology. More specifically, the present invention relates to pregnancy specific glycoprotein (PSG).
  • PSG pregnancy specific glycoprotein
  • IVF in vitro fertilization
  • COH controlled ovarian hyperstimulation
  • FSH follicle stimulating hormone
  • LH luteinizing hormone
  • ovulation Just prior to ovulation, multiple in vivo matured oocytes are removed from the ovaries.
  • the isolated mature oocytes are subsequently fertilized in vitro and cultured, typically for three to six days, before transferring the developed embryos back into the uterus at the 4-8 cell stage.
  • COH treatments are not successful in about one of five couples and are not recommended for a number of females, such as those females with polycystic ovary disease.
  • the exogenous hormone treatments used in COH treatments can over-stimulate follicular development and maturation of follicles.
  • OHSS ovarian hyperstimulation syndrome
  • women undergoing COH must be closely monitored by daily ultrasound examinations of the ovaries and blood hormone measurements.
  • IVF protocols that reduce the occurrence of OHSS.
  • the protocols should reduce or eliminate the amount of exogenous hormones administered to induce maturation of oocytes.
  • the present invention satisfies these needs.
  • An oocyte may be matured in vitro by providing a composition comprising an immature oocyte.
  • a pregnancy specific glycoprotein may then be added to the composition, thereby inducing maturation of the oocyte.
  • the mature oocyte may be used to produce an embryo by contacting the mature oocyte with sperm.
  • the embryo may be implanted into the uterus of a female capable of carrying the embryo to term.
  • the pregnancy specific glycoprotein may be PSGl, PSG2, PSG3, PSG4, PSG5, PSG6, PSG7, PSG8, PSG9, PSGlO or PSGI l.
  • Figure 1 shows the percentage of cumulus-oocyte complexes expanded following treatment with the indicated concentration of PSG5.
  • the present invention is related to the discovery that PSG induces the maturation of oocytes in vitro. By inducing the maturation of oocytes in vitro using PSG, the amount of exogenous hormones administered in IVF treatment protocols may be reduced. 1. In Vitro Maturation
  • PSG may be used for the in vitro maturation of oocytes.
  • An immature oocyte may be retrieved from a female while the oocyte is at a stage of development including, but not limited to, early antral and antral follicles.
  • the immature oocyte may be retrieved from a female that has not undergone external hormonal therapy.
  • the immature oocyte may be retrieved from a female that has undergone external hormonal therapy.
  • the female may have been administered a hormone including, but not limited to, GnRH, FSH, LH or hCG.
  • the hormone may have been administered in combination with another hormone or sequentially in any order.
  • the immature oocyte may be retrieved from the female by methods including, but not limited to, echography and aspiration.
  • the immature oocyte may be cryopreserved after isolation and thawed at a later time for in vitro maturation. b. Maturation
  • the isolated immature oocyte may be incubated in a culture medium comprising PSG.
  • the culture medium may be any physiologically acceptable culture medium including, but not limited to, TCM 199, ⁇ MEM and Ham's FlO.
  • the culture medium may optionally further comprise one or more other factors including, but not limited to, FSH, hCG, estradiol, cysteamine, sodium pyruvate, glutamine, autologous heat-inactivated serum and follicular fluid.
  • the immature oocyte may be incubated in the culture medium at temperatures including, but not limited to, from about 37 0 C to about 39 0 C for a period of " time including, but not limited to, about 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66 or 72 hours.
  • Trie oocyte may be incubated until maturation has occurred as evidenced by methods including, but not limited to, visual inspection under microscope of germinal vesicle break down (GVBD), cumulus expansion, metaphase II plate formation (Mil), or polar body extrusion.
  • a mature oocyte may be incubated with sperm in vitro to produce a mammalian embryo using standard in vitro fertilization methods as described in Textbook of Assisted Reproductive Techniques Laboratory & Clinical Perspectives, edited by Gardner, et al., 2001 Martin Ldunetz Ltd., London, the contents of which are incorporated herein by reference.
  • the embryo may be implanted into the uterus of a female capable of carrying the embryo to term.
  • PSG constitutes a major component of serum of pregnant women that may be essential for a successful pregnancy.
  • the PSG genes comprise a family of 11 highly conserved members. PSG is released into the maternal circulation and increases in concentration as pregnancy proceeds, reaching concentrations up to 400 ⁇ g/ml at term. The fact that PSG has functions other than maintenance of pregnancy by the female is evidenced by PSG mRNA being present in fetal liver, salivary gland, testis, and myeloid cells.
  • the PSG used to induce maturation may be any PSG that induces maturation of oocytes in vitro, including human PSG.
  • the human PSG may be PSGl, PSG2, PSG3, PSG4, PSG5, PSG6, PSG7, PSG8, PSG9, PSGlO or PSGl 1.
  • the PSG may also be an analog, derivative, fragment, homolog, or variant, or combination thereof, of PSGl 5 PSG2, PSG3, PSG4, PSG5, PSG6, PSG7, PSG8, PSG9, PSGlO or PSGl 1.
  • the analog, derivative, fragment, homolog or variant may have at least 75%, 80%, 85% or 90% sequence identity with a PSG, such as PSG5.
  • PSG fragments may comprise an Ig variable-like domain.
  • a PSG fragment may not comprise a signal peptide.
  • analog when used in the context of PSG, means a peptide or polypeptide comprising one or more non-standard amino acids or other structural variations from the conventional set of amino acids.
  • derivative when used in the context of PSG, means a peptide or polypeptide different other than in primary structure (amino acids and amino acid analogs).
  • derivatives may differ by being glycosylated, one form of post- translational modification.
  • peptides or polypeptides may exhibit glycosylation patterns due to expression in heterologous systems. If at least one biological activity is retained, then these peptides or polypeptides are derivatives.
  • fusion peptides or fusion polypeptides having a covalently modified N- or C-terminus PEGylated peptides or polypeptides, peptides or polypeptides associated with lipid moieties, alkylated peptides or polypeptides, peptides or polypeptides linked via an amino acid side-chain functional group to other peptides, polypeptides or chemicals, and additional modifications as would be understood in the art.
  • fragment when used in the context of PSG, means a peptide of from about 8 to about 50 amino acids in length.
  • the fragment may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 2 ⁇ ⁇ , 2% 23724, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 4O,
  • homolog when used in the context of PSG, means a peptide or polypeptide sharing a common evolutionary ancestor.
  • variant when used in the context of PSG, means a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity.
  • biological activity includes, but is not limited to, the ability to be bound by a specific antibody.
  • PMSG (5 IU/female, Calbiochem 367222) was used to prime 7 to 8-week-old CD-I female mice (35 total; Charles River). The mice were sacrificed 48 h later by progressive hypoxemia. Alcohol (70%) was applied to the abdominal region of the animals to clean the area and also to decrease contamination of samples with hair. A ventral incision was made to expose the abdominal cavity. The ovaries connected to oviducts were cut away from the uterine horn and the visceral adipose.
  • the ovary/oviduct samples were placed in a 15 ml tubes (10 per tube, Corning 430052) containing 3 ml of L-15 medium (Gibco 11415-064) plus 10% fetal calf serum (FCS; Invitrogen 16000-044). The ovary/oviduct samples were maintained at 37°C. [0027] The ovary/oviduct samples were then transferred to a Petri dish (Falcon 353004, 60x15 mm).
  • Cumulus-intact oocytes with homogeneous cytoplasm were selected from COCs prepared as described in Example 1 using a low-power (20-30 X) stereomicroscope and transferred using mouth glass pipets to 96-well plates (2/well) containing 90 ⁇ l culture media ( ⁇ MEM (Gibco 32571-036) with 10% FCS and PenStrep-Antibiotics (Invitrogen 15140-122)) per well mineral oil. Before addition of the COCs to the 96-well plate, the medium in the plate was pre- equilibrated for a period of 1 h at 37°C in a humidified incubator with 5% CO 2 in air.
  • PSG5 was added to each well in a volume of 10 ⁇ l so that the final volume in each well was 100 ⁇ l.
  • Each plate contained 4 wells of a "Negative Control” ( ⁇ MEM plus 10% FCS) and 4 wells of a “Positive Control” ( ⁇ MEM plus 10% FCS plus EGF (5 ng/ml, Sigma E-9644)). Two plates, duplicates, were run per assay, providing 2 wells per test protein. Proteins were diluted 1 :5 in IVM medium ( ⁇ MEM plus 10% FCS) before being added to the assay plates for a final dilution of 1 :50 in the assay.
  • Origin 7 SR3 v7.0475 (B475) indicates that the EC 50 for cumulus expansion with PSG5 was 0.64 ng/ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The use of PSG for the in vitro maturation of mammalian oocytes is described. The in vitro matured oocytes may be used for in vitro fertilization protocols.

Description

USE OF PREGNANCY SPECIFIC GLYCOPROTEIN FOR MATURATION OF OOCYTES
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional Application No. 60/614,773, filed September 30, 2004, the contents of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
1. Field of the Invention
[0002] The present invention is generally related to reproductive biology. More specifically, the present invention relates to pregnancy specific glycoprotein (PSG).
2. Description of Related Art
[0003] In vitro fertilization (IVF) of oocytes is a widely practiced medical technique used to overcome various forms of female and male infertility thereby providing for infertile couples. The standard IVF treatment is based on controlled ovarian hyperstimulation (COH) of female patients using exogenous hormones to induce the maturation of oocytes. The treatment is typically initiated by administering a gonadotropin releasing hormone (GnRH) agonist or antagonist to suppress the patient's own follicle stimulating hormone (FSH) and luteinizing hormone (LH). This is followed by injections of exogenous gonadotropins, e.g. FSH and/or LH, in order to ensure development of multiple preovulatory follicles. Just prior to ovulation, multiple in vivo matured oocytes are removed from the ovaries. The isolated mature oocytes are subsequently fertilized in vitro and cultured, typically for three to six days, before transferring the developed embryos back into the uterus at the 4-8 cell stage.
[0004] COH treatments are not successful in about one of five couples and are not recommended for a number of females, such as those females with polycystic ovary disease. Moreover, the exogenous hormone treatments used in COH treatments can over-stimulate follicular development and maturation of follicles. A subset of patients undergoing COH suffers from ovarian hyperstimulation syndrome (OHSS), which is a serious and potentially fatal condition. As a result, women undergoing COH must be closely monitored by daily ultrasound examinations of the ovaries and blood hormone measurements. [0005] Due to the limitations of standard IVF treatments using COH, various alternative protocols have been suggested. One way to alleviate the risks, side effects, and economic disadvantages of COH protocols involves the retrieval of immature oocytes followed by maturation of the oocytes in vitro. In this approach, the female is without stimulation, or receives reduced stimulation, and the retrieved oocytes are subjected to hormonal treatment in vitro. In vitro maturation (IVM) of oocytes would allow a reduction or elimination of the amounts of exogenous hormones typically administered, thereby reducing the problems discussed.
[0006] Despite the success of IVF, there is a significant need for improved methods of infertility treatment. In particular, there is a significant need to develop methods of maturing oocytes in vitro.
SUMMARY OF THE INVENTION
[0007] What the art needs are IVF protocols that reduce the occurrence of OHSS. The protocols should reduce or eliminate the amount of exogenous hormones administered to induce maturation of oocytes. The present invention satisfies these needs.
[0008] An oocyte may be matured in vitro by providing a composition comprising an immature oocyte. A pregnancy specific glycoprotein may then be added to the composition, thereby inducing maturation of the oocyte. The mature oocyte may be used to produce an embryo by contacting the mature oocyte with sperm. The embryo may be implanted into the uterus of a female capable of carrying the embryo to term. The pregnancy specific glycoprotein may be PSGl, PSG2, PSG3, PSG4, PSG5, PSG6, PSG7, PSG8, PSG9, PSGlO or PSGI l.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] Figure 1 shows the percentage of cumulus-oocyte complexes expanded following treatment with the indicated concentration of PSG5.
DETAILED DESCRIPTION OF THE INVENTION
[0010] The present invention is related to the discovery that PSG induces the maturation of oocytes in vitro. By inducing the maturation of oocytes in vitro using PSG, the amount of exogenous hormones administered in IVF treatment protocols may be reduced. 1. In Vitro Maturation
[0011] PSG may be used for the in vitro maturation of oocytes. a. Oocytes
[0012] An immature oocyte may be retrieved from a female while the oocyte is at a stage of development including, but not limited to, early antral and antral follicles.
[0013] The immature oocyte may be retrieved from a female that has not undergone external hormonal therapy. Alternatively, the immature oocyte may be retrieved from a female that has undergone external hormonal therapy. The female may have been administered a hormone including, but not limited to, GnRH, FSH, LH or hCG. The hormone may have been administered in combination with another hormone or sequentially in any order.
[0014] The immature oocyte may be retrieved from the female by methods including, but not limited to, echography and aspiration. The immature oocyte may be cryopreserved after isolation and thawed at a later time for in vitro maturation. b. Maturation
[0015] The isolated immature oocyte may be incubated in a culture medium comprising PSG. The culture medium may be any physiologically acceptable culture medium including, but not limited to, TCM 199, αMEM and Ham's FlO. The culture medium may optionally further comprise one or more other factors including, but not limited to, FSH, hCG, estradiol, cysteamine, sodium pyruvate, glutamine, autologous heat-inactivated serum and follicular fluid. [0016] The immature oocyte may be incubated in the culture medium at temperatures including, but not limited to, from about 370C to about 390C for a period of" time including, but not limited to, about 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66 or 72 hours. Trie oocyte may be incubated until maturation has occurred as evidenced by methods including, but not limited to, visual inspection under microscope of germinal vesicle break down (GVBD), cumulus expansion, metaphase II plate formation (Mil), or polar body extrusion. c. Embryo Production
[0017] A mature oocyte may be incubated with sperm in vitro to produce a mammalian embryo using standard in vitro fertilization methods as described in Textbook of Assisted Reproductive Techniques Laboratory & Clinical Perspectives, edited by Gardner, et al., 2001 Martin Ldunetz Ltd., London, the contents of which are incorporated herein by reference. The embryo may be implanted into the uterus of a female capable of carrying the embryo to term. 2. Pregnancy Specific Glycoprotein
[0018] PSG constitutes a major component of serum of pregnant women that may be essential for a successful pregnancy. The PSG genes comprise a family of 11 highly conserved members. PSG is released into the maternal circulation and increases in concentration as pregnancy proceeds, reaching concentrations up to 400 μg/ml at term. The fact that PSG has functions other than maintenance of pregnancy by the female is evidenced by PSG mRNA being present in fetal liver, salivary gland, testis, and myeloid cells.
[0019] The PSG used to induce maturation may be any PSG that induces maturation of oocytes in vitro, including human PSG. The human PSG may be PSGl, PSG2, PSG3, PSG4, PSG5, PSG6, PSG7, PSG8, PSG9, PSGlO or PSGl 1. The PSG may also be an analog, derivative, fragment, homolog, or variant, or combination thereof, of PSGl5 PSG2, PSG3, PSG4, PSG5, PSG6, PSG7, PSG8, PSG9, PSGlO or PSGl 1. The analog, derivative, fragment, homolog or variant may have at least 75%, 80%, 85% or 90% sequence identity with a PSG, such as PSG5. PSG fragments may comprise an Ig variable-like domain. A PSG fragment may not comprise a signal peptide.
[0020] As used herein, the term "analog", when used in the context of PSG, means a peptide or polypeptide comprising one or more non-standard amino acids or other structural variations from the conventional set of amino acids.
[0021] As used herein, the term "derivative", when used in the context of PSG, means a peptide or polypeptide different other than in primary structure (amino acids and amino acid analogs). By way of illustration, derivatives may differ by being glycosylated, one form of post- translational modification. For example, peptides or polypeptides may exhibit glycosylation patterns due to expression in heterologous systems. If at least one biological activity is retained, then these peptides or polypeptides are derivatives. Other derivatives include, but are not limited to, fusion peptides or fusion polypeptides having a covalently modified N- or C-terminus, PEGylated peptides or polypeptides, peptides or polypeptides associated with lipid moieties, alkylated peptides or polypeptides, peptides or polypeptides linked via an amino acid side-chain functional group to other peptides, polypeptides or chemicals, and additional modifications as would be understood in the art.
[0022] As used herein, the term "fragment", when used in the context of PSG, means a peptide of from about 8 to about 50 amino acids in length. The fragment may be 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 2Ϊ~, 2% 23724, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 4O,
41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 amino acids in length.
[0023] As used herein, the term "homolog", when used in the context of PSG, means a peptide or polypeptide sharing a common evolutionary ancestor.
[0024] As used herein, the term "variant", when used in the context of PSG, means a peptide or polypeptide that differs in amino acid sequence by the insertion, deletion, or conservative substitution of amino acids, but retain at least one biological activity. For purposes of the present invention, "biological activity" includes, but is not limited to, the ability to be bound by a specific antibody.
[0025] The present invention has multiple aspects, illustrated by the following non-limiting examples.
EXAMPLES
Example 1 Isolation Of Murine Cumulus-Oocyte Complex
[0026] PMSG (5 IU/female, Calbiochem 367222) was used to prime 7 to 8-week-old CD-I female mice (35 total; Charles River). The mice were sacrificed 48 h later by progressive hypoxemia. Alcohol (70%) was applied to the abdominal region of the animals to clean the area and also to decrease contamination of samples with hair. A ventral incision was made to expose the abdominal cavity. The ovaries connected to oviducts were cut away from the uterine horn and the visceral adipose. The ovary/oviduct samples were placed in a 15 ml tubes (10 per tube, Corning 430052) containing 3 ml of L-15 medium (Gibco 11415-064) plus 10% fetal calf serum (FCS; Invitrogen 16000-044). The ovary/oviduct samples were maintained at 37°C. [0027] The ovary/oviduct samples were then transferred to a Petri dish (Falcon 353004, 60x15 mm). Under a stereomicroscope (Nikon SM2-800 with thermo-plate heating stage) using a pair of scissors needle (27 gauge) mounted in a 1 ml tuberculin syringe, the ovaries and oviduct were cleaned of the fatty pad and placed in a new Petri dish filled with 2-3 ml of fresh medium (L-15 + 10% FCS). The COCs were recovered by mechanical rupture of each ovary with needles and placed in a new Petri dish filled with 2-3 ml of fresh medium (L-15 + 10% FCS). Example 2 Effect Of PSG5 On The In Vitro Cumulus Expansion Of The Cumulus-Oocyte Complex
[0028] Cumulus-intact oocytes with homogeneous cytoplasm were selected from COCs prepared as described in Example 1 using a low-power (20-30 X) stereomicroscope and transferred using mouth glass pipets to 96-well plates (2/well) containing 90 μl culture media (αMEM (Gibco 32571-036) with 10% FCS and PenStrep-Antibiotics (Invitrogen 15140-122)) per well mineral oil. Before addition of the COCs to the 96-well plate, the medium in the plate was pre- equilibrated for a period of 1 h at 37°C in a humidified incubator with 5% CO2 in air. [0029] PSG5 was added to each well in a volume of 10 μl so that the final volume in each well was 100 μl. Each plate contained 4 wells of a "Negative Control" (αMEM plus 10% FCS) and 4 wells of a "Positive Control" (αMEM plus 10% FCS plus EGF (5 ng/ml, Sigma E-9644)). Two plates, duplicates, were run per assay, providing 2 wells per test protein. Proteins were diluted 1 :5 in IVM medium (αMEM plus 10% FCS) before being added to the assay plates for a final dilution of 1 :50 in the assay.
[0030] The plates containing the treated COCs were incubated for 18 h at 370C in a humidified incubator with 5% CO2 in air. Each COC was then visually inspected using a Nikon Inverted Microscope to identify the formation of a mucoid extracellular matrix by cumulus cells, which is an indicator of cumulus expansion. The percentage of cumulus expansion was defined as the number of expanded COCs in relation to the total COCs that were used in each treatment group. [0031] PSG5 induced expansion of 60% of the COCs in the primary assay. The effect of PSG5 on COC expansion was then retested in a reconfirmation assay, which indicated that PS G5 induced expansion in 100% of the COCs tested.
[0032] In both the primary assay and the reconfirmation assays, the COCs in the negative controls (no EGF) or the positive controls (plus EGF) wells were always 0% or 100% expanded, respectively (data not shown).
Example 3 Dose-Response Analysis Of PSG5
[0033] Based on the results from the preliminary and reconfirmation assays described in Example 2, dose-response analysis was performed for PSG5. Dose-response testing was performed similar to the method described in Example 2, except 3 wells with 4-5 COCs per well were assigned to each protein concentration. Dilutions of the test proteins were made depending on the concentration of the particular proteins, which were sometimes not diluted before being added to the assay, resulting in a final concentration of 1 : 10.
[0034] The results of the dose-response analysis of PSG5 appear in Figure 1. Analysis with
Origin 7 SR3 v7.0475 (B475) indicates that the EC50 for cumulus expansion with PSG5 was 0.64 ng/ml.
[0035] The description is not limited to the above representative embodiments.

Claims

CLAIMSWhat is claimed is:
1. A method of maturing an oocyte in vitro comprising:
(a) providing an immature oocyte; and
(b) contracting the oocyte with pregnancy specific glycoprotein.
2. The method of claim 1 wherein the pregnancy specific glycoprotein is selected from the group consisting of PSGl, PSG2, PSG3, PSG4, PSG5, PSG6, PSG7, PSG8, PSG9, PSGlO and PSGI l .
3. The method of claim 2 wherein the pregnancy specific glycoprotein is PSG5 or a polypeptide at least 80% identical thereto.
4. The method of claim 1 wherein the immature oocyte is derived from a female that has not undergone external hormonal therapy.
5. The method of claim 1 wherein the immature oocyte is derived from a female that has undergone external hormonal therapy.
6. The method of claim 5 wherein the female was administered a hormone selected from the group consisting of GnRH, FSH, LH, hCG, and a combination thereof.
7. The method of claim 1 wherein the immature oocyte is provided in a culture medium comprising a factor selected from the group consisting of FSH, hCG, estrachol, cysteamine, sodium pyruvate, glutamine, autologous heat-inactivated serum, and follicular fluid.
8. A mature oocyte produced by the method of claim 1.
9. A method of producing an embryo in vitro comprising treating a mature oocyte with sperm, wherein said oocyte is produced by the method of claim 1.
10. A method of in vitro fertilization comprising implanting an embryo in need thereof, wherein said embryo is produced by a method comprising treating a mature oocyte with sperm, wherein said oocyte is produced by the method of claim 1.
PCT/US2005/035386 2004-09-30 2005-09-30 Use of pregnancy specific glycoprotein for maturation of oocytes WO2006039604A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US11/575,398 US20070282162A1 (en) 2004-09-30 2005-09-30 Use of pregnancy specific glycoprotein for maturation of oocytes
EP05803981A EP1794286A1 (en) 2004-09-30 2005-09-30 Use of pregnancy specific glycoprotein for maturation of oocytes
AU2005292374A AU2005292374A1 (en) 2004-09-30 2005-09-30 Use of pregnancy specific glycoprotein for maturation of oocytes
JP2007534835A JP2008514239A (en) 2004-09-30 2005-09-30 Use of pregnancy-specific glycoprotein for oocyte maturation
CA002581048A CA2581048A1 (en) 2004-09-30 2005-09-30 Use of pregnancy specific glycoprotein for maturation of oocytes
IL181907A IL181907A0 (en) 2004-09-30 2007-03-13 Use of pregnancy specific glycoprotein for maturation of oocytes
NO20072159A NO20072159L (en) 2004-09-30 2007-04-26 Use of pregnancy-specific glycoprotein for the maturation of oocytes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61477304P 2004-09-30 2004-09-30
US60/614,773 2004-09-30

Publications (1)

Publication Number Publication Date
WO2006039604A1 true WO2006039604A1 (en) 2006-04-13

Family

ID=35539281

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/035386 WO2006039604A1 (en) 2004-09-30 2005-09-30 Use of pregnancy specific glycoprotein for maturation of oocytes

Country Status (8)

Country Link
US (1) US20070282162A1 (en)
EP (1) EP1794286A1 (en)
JP (1) JP2008514239A (en)
AU (1) AU2005292374A1 (en)
CA (1) CA2581048A1 (en)
IL (1) IL181907A0 (en)
NO (1) NO20072159L (en)
WO (1) WO2006039604A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20163349A1 (en) * 2016-05-11 2017-11-11 Gionas S R L FOLLICULAR LIQUID

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113943698B (en) * 2021-12-20 2022-03-01 北京亿里生物科技发展有限公司 Method for in vitro maturation culture of oocyte and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169835A (en) * 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications
WO2002048316A1 (en) * 2000-12-13 2002-06-20 Vrije Universiteit Brussel Method for in vitro culture of ovarian follicles
WO2003076600A2 (en) * 2002-03-08 2003-09-18 Mcgill University In vitro maturation of immature human oocytes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124092A1 (en) * 2001-06-21 2003-07-03 Eugene Medlock IL-17 like molecules and uses thereoflike molecules and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169835A (en) * 1989-01-18 1992-12-08 Oklahoma Medical Research Foundation Pregancy specific proteins applications
WO2002048316A1 (en) * 2000-12-13 2002-06-20 Vrije Universiteit Brussel Method for in vitro culture of ovarian follicles
WO2003076600A2 (en) * 2002-03-08 2003-09-18 Mcgill University In vitro maturation of immature human oocytes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHA K-Y ET AL: "MATURATION IN VITRO OF IMMATURE HUMAN OOCYTES FOR CLINICAL USE", HUMAN REPRODUCTION UPDATE, OXFORD UNIVERSITY PRESS, OXFORD, GB, vol. 4, no. 2, March 1998 (1998-03-01), pages 103 - 120, XP009014115 *
SNYDER SARA K ET AL: "Pregnancy-specific glycoproteins function as immunomodulators by inducing secretion of IL-10, IL-6 and TGF-beta1 by human monocytes", AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, vol. 45, no. 4, April 2001 (2001-04-01), pages 205 - 216, XP002363585, ISSN: 1046-7408 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITUA20163349A1 (en) * 2016-05-11 2017-11-11 Gionas S R L FOLLICULAR LIQUID
EP3243518A1 (en) * 2016-05-11 2017-11-15 Gionas S.r.l. Follicular fluid
WO2017195090A1 (en) * 2016-05-11 2017-11-16 Gionas S.R.L. Follicular fluid

Also Published As

Publication number Publication date
EP1794286A1 (en) 2007-06-13
IL181907A0 (en) 2007-07-04
CA2581048A1 (en) 2006-04-13
JP2008514239A (en) 2008-05-08
US20070282162A1 (en) 2007-12-06
AU2005292374A1 (en) 2006-04-13
NO20072159L (en) 2007-04-26

Similar Documents

Publication Publication Date Title
Lopata et al. In vitro fertilization of preovulatory oocytes and embryo transfer in infertile patients treated with clomiphene and human chorionic gonadotropin
Mikkelsen Strategies in human in-vitro maturation and their clinical outcome
Veeck et al. Maturation and fertilization of morphologically immature human oocytes in a program of in vitro fertilization
Nagy et al. Timing of oocyte activation, pronucleus formation and cleavage in humans after intracytoplasmic sperm injection (ICSI) with testicular spermatozoa and after ICSI or in-vitro fertilization on sibling oocytes with ejaculated spermatozoa.
Olivennes et al. Fertiliza1tion and early embryology: Four indications for embryo transfer at the blastocyst stage
Flood et al. Ooplasmic transfusion: prophase germinal vesicle oocytes made developmentally competent by microinjection of metaphase II egg cytoplasm
Plachot et al. Fertilization and early embryology: granulosa cells improve human embryo development in vitro
Lu et al. Different sperm sources and parameters can influence intracytoplasmic sperm injection outcomes before embryo implantation
Russell Immature oocyte retrieval combined with in-vitro oocyte maturation
Haouzi et al. Pertinence of apoptosis markers for the improvement of in vitro fertilization (IVF)
Staessen et al. Comparison between human serum and Albuminar-20 (TM) supplement for in-vitro fertilization
Aydos et al. Enzymatic digestion plus mechanical searching improves testicular sperm retrieval in non-obstructive azoospermia cases
Wongsrikeao et al. Effects of hexoses on in vitro oocyte maturation and embryo development in pigs
CA2578573C (en) Use of il-17- for maturation of oocytes
US20070282162A1 (en) Use of pregnancy specific glycoprotein for maturation of oocytes
Liu et al. Role of secreted proteins and gonadotrophins in promoting full maturation of porcine oocytes in vitro
Rehman et al. Role of Interleukin-I β in conception after intracytoplasmic sperm injection
Freeman et al. Coculture of mouse embryos with cells isolated from the human ovarian follicle, oviduct, and uterine endometrium
Russell Immature oocyte retrieval with in-vitro oocyte maturation
EP1135154B1 (en) Improvement of folliculogenesis
Al-Anbari et al. Relation of serum and follicular level of GDF9 to oocyte quality, embryo quality and pregnancy rate
von Otte et al. Lessons learned from introducing an in-vitro maturation programme into clinical practice
Buckett et al. In vitro maturation of oocytes
Zhang Progress of research on in vitro fertilization and embryo transfer in China
Hibbert et al. In Vitro Fertilization and the Oligozoospermic Male

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005292374

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2581048

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 181907

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 11575398

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2005292374

Country of ref document: AU

Date of ref document: 20050930

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2005292374

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007534835

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005803981

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005803981

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 11575398

Country of ref document: US